erlotinib hydrochloride has been researched along with Inflammatory Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Hiemstra, CN; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ | 1 |
| Buchholz, T; Debeb, BG; Gong, Y; Klopp, A; Krishnamurthy, S; Lacerda, L; Larson, R; Levy, LB; Smith, D; Solley, T; Ueno, NT; Woodward, WA; Xu, W | 1 |
2 other study(ies) available for erlotinib hydrochloride and Inflammatory Breast Neoplasms
| Article | Year |
|---|---|
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.
Topics: Animals; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Culture Media, Conditioned; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterografts; Humans; Inflammatory Breast Neoplasms; Mesenchymal Stem Cells; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Signal Transduction; Stromal Cells; Tumor Burden | 2015 |